Gennex Laboratories Share Price
30 Oct, 2026 4:01 PM (IST)
Gennex Laboratories Performance
- Today's Low
- ₹8
- Today's High
- ₹9
- 52 Week Low
- ₹7
- 52 Week High
- ₹17
- Open Price₹9
- Previous Close₹9
- Volume1,321,688
- 50 DMA₹9.80
- 100 DMA₹10.20
- 200 DMA₹10.80
Gennex Laboratories Chart
Investment Returns
- Over 1 Month -20.44%
- Over 3 Month -9.58%
- Over 6 Month -20.67%
- Over 1 Year -51.48%
Smart Investing Starts Here Start SIP with Gennex Laboratories for Steady Growth!
Gennex Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 8.2
- PEG Ratio
- 0.2
- Market Cap Cr
- 195
- P/B Ratio
- 0.9
- Average True Range
- 0.6
- EPS
- 1
- Dividend Yield
- 0
- MACD Signal
- -0.5
- RSI
- 26.46
- MFI
- 14.08
Latest Stock News Updates
With reference to the captioned subject matter, pursuant to regulation 74(5) of SEBI (DP) Regulations, 2018, we hereby submit the certificate received from the M/s R&D Infotech Private Limited, Registrar and Share Transfer Agent of the Company for the Quarter ended September 30, 2026. We request you to take the above information on record and acknowledge the receipt of the same.
- BSE India
- 2 weeks 3 days ago
In compliance to Regulation 44 of SEBI (LODR) Regulations, 2015, as amended from time to time, please find enclosed herewith voting results of the 41st eAGM of the Company held on September 30, 2026 at 12.30 Hrs through VC/OAVM along with the consolidated Scrutinizers report. It is to inform that all resolutions set out in the notice of the 41st eAGM were duly approved by shareholders with requisite majority. The voting results along with Scrutinizers report is also being enclosed to this letter and uploaded on the website of the Company i.e. www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same.
- BSE India
- 4 weeks 1 day ago
In compliance to Regulation 44 of SEBI (LODR) Regulations, 2015, as amended from time to time, please find enclosed herewith voting results of the 41st eAGM of the Company held on September 30, 2026 at 12.30 Hrs through VC/OAVM along with the consolidated Scrutinizers report. It is to inform that all resolutions set out in the notice of the 41st eAGM were duly approved by shareholders with requisite majority. The voting results along with Scrutinizers report is also being enclosed to this letter and uploaded on the website of the Company i.e. www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same.
- BSE India
- 4 weeks 1 day ago
Gennex Laboratories Financials
Gennex Laboratories Technicals
EMA & SMA
- Bearish Moving Average 16
- Bullish Moving Average 0
- 20 Day
- ₹9.20
- 50 Day
- ₹9.80
- 100 Day
- ₹10.20
- 200 Day
- ₹10.80
Resistance and Support
- R3 10.30
- R2 9.70
- R1 8.90
- S1 7.40
- S2 6.90
- S3 6.00
Gennex Laboratories Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-09-04 | A.G.M. | |
| 2026-08-14 | Quarterly Results | |
| 2026-05-30 | Audited Results | |
| 2026-04-16 | Others | Inter-alia, to consider 1. Decide regarding the conduct of EGM for Regularization of Additional Director Ms. Khushbu Kachhawa as a Director. 2. Appoint Scrutinizer for EGM. 3. Other business matters. |
| 2026-02-14 | Quarterly Results |
About Gennex Laboratories
Gennex Laboratories is engaged in the business of manufacturing of Bulk Drugs and Intermediaries. View More- NSE Symbol
- GENNEX
- BSE Symbol
- 531739
- ISIN
- INE509C01026
Similar Stocks to Gennex Laboratories
Popular Stocks
Gennex Laboratories FAQs
Gennex Laboratories share price is ₹8 As on 31 October, 2026 | 05:48
The Market Cap of Gennex Laboratories is ₹194.8 Cr As on 31 October, 2026 | 05:48
The P/E ratio of Gennex Laboratories is 8.2 As on 31 October, 2026 | 05:48
The PB ratio of Gennex Laboratories is 0.9 As on 31 October, 2026 | 05:48
The 52 week High & Low of Gennex Laboratories is ₹17/₹7 respectively As on 31 October, 2026 | 05:48
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.